ROLE OF CLINICAL PHARMACIST IN ASSESSMENT OF DRUG RELATED PROBLEMS OF CARDIOVASCULAR AGENTS IN DEPARTMENT OF CARDIOLOGY IN A TERTIARY CARE HOSPITAL – A PROSPECTIVE OBSERVATIONAL STUDY
In total of 173 prescriptions of the patient, the total number of 329 drug interactions (DIs) was found, in which the 240 interactions were found in male and 89 in the female bearing 72.90% and 27.10%, respectively. Patient was of various age groups, in which the maximum frequency was seen in the age group of 61–70 years having 105 interactions bearing the percentage of 31.9%. According to the participation of different age group of the male and female with their corresponding age. The participation of male is high having frequency of 240 (72.9%) than female participation of frequency 89 (27.1%). The participation of male in the age group of 61–70 years is 83 and the female is 40 in the age group of 51–60 years. Potential DIs (PDIs) were categorized based on the gender. In that compared to 13 (40.6) females, males 19 (59.4%) were found to have more PDIs. Our study is more PDIs in adult patients. Because in adults lacking of nutrition’s and in elderly patients multiple prescribers, multiple drugs and multiple diseases. The number of potential drug-DI (PDDI) increased with an increase in the number of drugs prescribed. The numbers of drug prescribed increase with age. This DI has a potential to increase or decrease the therapeutic effect or to increase the risk of adverse drug reaction. An increased awareness of PDDIs, rational coprescription of drugs, and a close monitoring of patients in whom these drugs are prescribed are recommended. The recommendation is based on the special monitoring and the perspiration of the clinical pharmacist. The DI observed in the geriatric patient is more severe and common in compared to the other groups of study. The geriatric patient is physiological disability in correspond with the first-pass metabolism and the presence of the other diseases which also enables the multiple prescriptions causing polypharmacy. The gender specification also the cause of the interaction, the female is more prone to the DI due to the hormonal distribution in the body and inability of the physiological function to absorb and the distribution. The special training should be provided to the pharmacist for looking forward of the geriatric patient and female patient. The training regarding the prescription their adherence, use, toxicity, and dosage regimen is being properly enabled in the training for the practical application. This study helps to know the different interaction related to the cardiovascular agent with own class of the drug and the other class of drugs used therapeutically to care the disease.
2. Ragesh G, Ushasri M, Sindhubharathi A, Srinivasulu A. A study on assessment of clinical pharmacy services to cardiology department in tertiary care teaching hospital. Int J Pharm Pharm Sci 2014;6:192-5.
3. Mendes-Netto RS, Silva CQ, Dias A, Rocha CE, Lyra-Junior DP. Assessment of drug interactions in elderly patients of a family health care unit in Aracaju (Brazil): A pilot study. Afr J Pharm Pharmacol 2011;5:812-8.
4. Murtaza G, Khan MY, Azhar S, Khan SA, Khan TM. Assessment of potential drug drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharm J 2015;14:1-6.
5. Bacic-Vrca V, Marusic S, Erdeljic V, Falamic S, Gojo-Tomic N, Rahelic D, et al. The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci 2010;32:815-21.
6. Hegde S, Udaykumar P, Manjuprasad MS. Potential drug interactions in chronic kidney disease patients a cross sectional study. Int J Recent Trends Sci Technol 2015;16:56-60.
7. Cruciol-Souza JM, Thomson JC. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci 2006;9:427-33.
8. Mateti U, Rajakannan T, Nekkanti H, Rajesh V, Mallaysamy S, Ramachandran P, et al. Drug-drug interactions in hospitalized cardiac patients. J Young Pharm 2011;3:329-33.
9. Murtaza G, Khan MY, Azhar S, Khan SA, Khan TM. Assessment of potential drug drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharm J 2015;14:1-6.
10. Ismail M, Khattak MB, Iqbal Z, Javaid A. Potential drug drug interaction in cardiology ward of teachinghospital. Healthmed 2012;6:1618-24.
11. Chelkeba L, Alemseged F, Bedada W. Assessment of potential drug drug interaction among outpatient receiving cardiovascular medication at Jimma University specialized hospital, South West Ethiopia. Int J Basic Clin Pharmacol 2013;2:144-52.
12. Rahmawati F, Rochmah F, Hidayati N, Sulaiman SA. Potentiality of drug drug interaction in hospitalized geriatrics patient in a private hospital. Asian J Pharm Clin Res 2010;3:191-4.
13. Kumar K, et al. Clopidogrel an overview. Int J Pharmacol Res 2013;1:1-7.
14. Pasina L, Djade CD, Nobili A, Tettamanti M, Franchi C, Salerno F, et al. Drug-drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiol Drug Saf 2013;22:1054-60.
15. Dunn SP, Pharma D, et al. Study of drug drug interaction in cardiovascular catheterization and intervention. JAAC J 2012;5:
16. Kumar J, Jaskumar P, Sunny AA, Suthar MK. Assessment of potential drug drug interaction in prescription of patient with chronic disease in a community setting. J Pharm Res 2015;14:47.
17. Kapadia J, Thakor D, Desai C, Dikshit RK. A study of potential drug drug interaction in indoor patient of medicine department at a tertiary care hospital. J Appl Pharm Sci 2013;3:89-96.
18. Patel VK, Acharya LD, Rajakannan T, Surulivelrajan M, Guddattu V, Padmakumar R, et al. Potential drug interactions in patients admitted to cardiology wards of a South Indian teaching hospital. Australas Med J 2011;4:9-14.
19. Sharma S, Chhetri HP, Alam K. A study of potential drug-drug interactions among hospitalized cardiac patients in a teaching hospital in western nepal. Indian J Pharmacol 2014;46:152-6.
20. Magro L, Conforti A, Del Zotti F, Leone R, Iorio ML, Meneghelli I, et al. Identification of severe potential drug-drug interactions using an italian general-practitioner database. Eur J Clin Pharmacol 2008;64:303-9.
21. Kothari N, Ganguly B. Potential drug drug interactions among medications prescribed to hypertensive patients. J Clin Diagn Res 2014;8:HC01-4.
22. Aghajani MH, Sistanizad M, Abbasinazari M, Ghamsari MA, Ayazkhoo L, Safi O, et al. Potential drug-drug interactions in post-CCU of a teaching hospital. Iran J Pharm Res 2013;12:243-8.
23. Sepehri G, Khazaelli P, Dahooie FA, Sepehri E, Dehghani MR. Prevalence of potential drug drug interaction in an Iranian general Hospital. Indian J Pharm Sci 2012;74:75-9.
24. Raquel S. Mendes-nettoeta assessment of drug interactions in elderly patients of a family health care unit in Aracaju (Brazil): A pilot study. Afr J Pharm Pharmacol 2011;5:812-8.
25. Umretiya T, Patil NR, Manjunath G, Kumar C. Assessment of potential drug-drug interactions in the department of medicine at Basaweshwara teaching and general hospital Gulbarga. RGUHS J Pharm Sci 2015;5:90-6.
26. Bacic-Vrca V, Marusic S, Erdeljic V, Falamic S, Gojo-Tomic N, Rahelic D, et al. The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci 2010;32:815-21.
27. Hammes JA, Pfuetzenreiter F, Silveira FD, Koenig A, Westphal GA. Potential drug interactions prevalence in intensive care units. Rev Bras Ter Intensiva 2008;20:349-54.
28. Cremaden J, Gonzalo M, Arrebola I. Relationship between drug interaction related negative clinical outcomes. Pharm Pract 2007;5:46-9.
29. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor xa inhibitor. Am J Cardiovasc Drugs 2013;13:331-42.
30. Bista D, Palaian S, Shankar PR, Prabhu MM, Paudel R, Mishra P, et al. Understanding the essentials of drug interactions: A potential need for safe and effective use of drugs. Kathmandu Univ Med J (KUMJ) 2007;5:421-30.
This work is licensed under a Creative Commons Attribution 4.0 International License.